Moleculin Biotech (NASDAQ:MBRX) Share Price Passes Above 50-Day Moving Average – Here’s What Happened

Moleculin Biotech, Inc. (NASDAQ:MBRX) shares crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.35 and traded as high as $2.56. Moleculin Biotech shares last traded at $2.51, with a volume of 75,539 shares trading hands.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Moleculin Biotech in a research report on Tuesday, March 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Moleculin Biotech currently has a consensus rating of “Hold” and an average target price of $22.00.

Moleculin Biotech Stock Down 2.0%

The business has a 50-day moving average of $2.35 and a 200-day moving average of $5.41. The stock has a market cap of $13.39 million, a price-to-earnings ratio of -0.08 and a beta of 1.67.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.